GlassScriptPhysician profile
Thomas P Miller
NPI 1841210895
$6,579.36
in general payments reported to CMS, 2019-2025
23 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $560 · 2021: $849 · 2022: $962 · 2023: $909 · 2024: $1,230 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,433 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,432.56 |
| Education | $130.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,858.23 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $923.03 | 2019-2025 | |
| Glaxosmithkline, LLC. | $911.51 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Csl Behring | $457.43 | 2019-2025 | Hizentra, Haegarda |
| Genentech USA, INC. | $326.09 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $305.27 | 2019-2025 | Dupixent |
| Amgen INC. | $274.87 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $245.35 | 2021-2025 | Eohilia, Hyqvia, Cuvitru |
| Novartis Pharmaceuticals Corporation | $228.34 | 2024-2025 | |
| Alk-Abello, INC | $224.04 | 2019-2025 | Neffy, Grastek, Odactra |
| Phadia US INC. | $210.90 | 2021-2025 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $99.63 | 2020-2022 | |
| Lilly USA, LLC | $90.10 | 2024-2025 | Ebglyss, Olumiant |
| Ars Pharmaceuticals Operations, INC. | $86.25 | 2025 | Neffy |
| Grifols USA, LLC | $75.22 | 2022-2025 | Xembify |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $45.99 | 2020-2025 | |
| Aimmune Therapeutics, INC. | $43.50 | 2021-2022 | |
| Optinose US, INC. | $43.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $37.29 | 2021-2023 | |
| Kaleo, INC. | $33.66 | 2022-2023 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.23 | 2019-2021 | |
| Leo Pharma INC. | $18.28 | 2024 | Adbry |
| Hikma Pharmaceuticals USA | $13.01 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.